Publications by authors named "Loan Honeywell"
Background: The humanized anti-CGRP monoclonal antibody eptinezumab has been evaluated in five large-scale clinical trials conducted in patients with migraine. This integrated analysis was conducted to evaluate the comprehensive safety and tolerability of eptinezumab in patients with migraine across these studies.
Methods: Data were pooled from four randomized, double-blind, placebo-controlled studies and the first year of one open-label study.